MULTI-ANCESTRY WHOLE GENOME SEQUENCING (WGS) AND META-ANALYSIS TO IDENTIFY LOCI ASSOCIATED WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)

<div><p><b>Background: </b>Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of chronic liver disease in the US. Notably, disease prevalence differs greatly by race/ethnicity, with the highest prevalence in those of Hispanic and Asian ancestry, and the lowest prevalence in those of African ancestry. To date, studies have identified common variants associated with MASLD in predominantly European or American populations.

MORTALITY, HEPATIC DECOMPENSATION, AND CARDIOVASCULAR OUTCOMES IN LEAN VS. NON-LEAN MASH CIRRHOSIS: A VETERANS AFFAIRS COHORT STUDY

<div><p><b>Background: </b>Studies on incident liver and cardiovascular outcomes in lean (body mass index: BMI &lt;25 kg/m<sup>2</sup>, or &lt;23 kg/m<sup>2</sup> for Asians) vs. non-lean individuals with metabolic dysfunction-associated steatohepatitis (MASH) have reported mixed results. We aimed to compare incident clinical outcomes and mortality between lean and non-lean individuals with compensated MASH cirrhosis in a large national cohort.</p>

FIBROSIS IMPROVEMENT WITH PEGOZAFERMIN TREATMENT IN MASH PATIENTS WITH F4 FIBROSIS: ANALYSIS FROM A 24-WEEK RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 TRIAL (ENLIVEN)

<div><p><b>Background:</p> </b><p>Metabolic dysfunction-associated steatohepatitis (MASH) patients who have developed stage F4 fibrosis (cirrhosis) are at risk of hepatic decompensation, hepatocellular carcinoma, liver transplant, cardiovascular events, liver and all-cause mortality. There are currently no approved therapies for non-cirrhotic or cirrhotic MASH.</p>

SERUM Z POLYMER LEVELS AND FACTORS AFFECTING INCREASED LIVER FIBROSIS ARE ASSOCIATED WITH FUTURE SEVERE LIVER DISEASE OUTCOMES IN A PROSPECTIVE COHORT OF ADULTS WITH ALPHA-1-ANTITRYPSIN DEFICIENCY .

<div><p><strong>Background</strong>: <span data-contrast="none" xml:lang="EN-US" lang="EN-US" class="TextRun SCXW199784672 BCX0"><span class="NormalTextRun SCXW199784672 BCX0" data-ccp-charstyle="x_x_normaltextrun">Outcomes of adults with ZZ alpha-1-antitrypsin deficiency (AATD) liver disease is variable and unpredictable. There is a lack of prospective data, including on the utility of liver biopsy.

FEASIBILITY AND RESULTS OF AN INPATIENT TELEHEPATOLOGY CONSULT SERVICE IN AN INTEGRATED HEALTH SYSTEM

<div><p><b>Background: </b>Providers at community hospitals often seek to transfer hospitalized patients with advanced liver disease to tertiary/quaternary care hospitals for further management due to lack of expertise in caring for these patients. However, it is possible to co-manage such patients at local hospitals by providing virtual consultation by tertiary care hepatologists via inpatient telehepatology (INP-TH) consultation.

CHARACTERIZING LINKAGE TO HEPATITIS C VIRUS CARE DURING AND FOLLOWING PREGNANCY: IDENTIFYING MISSED OPPORTUNITIES FOR TESTING AND TREATMENT

<div><p><b>Background: </b>With the ongoing opioid epidemic, hepatitis C virus (HCV) prevalence in women of childbearing potential has increased in North America. As pregnancy may be the only time many women interact with the healthcare system, it presents an opportune time for HCV screening and linkage to care. Poor postpartum follow-up may justify treatment in pregnancy, but there is currently little known about the cascade of care for women of childbearing potential with HCV in pregnancy or postpartum.</p>

INTRAHEPATIC CHANGES IN VIRAL AND IMMUNE MARKERS FOLLOWING TREATMENT WITH JNJ-73763989 (JNJ-3989) AND NUCLEOS(T)IDE ANALOGS (NAS), IN PATIENTS WITH CHRONIC HEPATITIS B (CHB): INSIGHT WEEK 40 (W40) INTERIM RESULTS

<div><p><b>Background: </b>Treatment of CHB with JNJ-3989 and NA &#177; JNJ-6379 has shown profound reductions in serum hepatitis B viral (HBV) markers. The INSIGHT study aims to assess intrahepatic changes in virological and immunological markers with JNJ-3989 based treatment in CHB patients.</p>

IDENTIFICATION OF THE ENVIRONMENTAL POLLUTANTS AND METABOLIC PATHWAYS ASSOCIATED WITH NONALCOHOLIC FATTY LIVER DISEASE SEVERITY

<div><p><b>Background: </b>Environmental pollutants are associated with disrupted hepatic metabolism and NAFLD. A pilot study (n=140) presented at AASLD elucidated exposures and metabolic pathways associated with NAFLD severity. To confirm these findings, a larger cross-sectional multi-‘omics study was performed in subjects with NAFLD. </p>

MACHINE LEARNING SCORES ACCURATELY CLASSIFY INDIVIDUALS AT INDETERMINATE RISK OF INCIDENT CIRRHOSIS INTO LOW AND HIGH RISK GROUPS

<div><p><b>Background: </b>Risk stratification in non-alcoholic fatty liver disease (NAFLD) using non-invasive scores including Fibrosis-4 (FIB4) and NAFLD fibrosis score (NFS) is recommended by clinical guidelines. However, FIB4 and NFS values are indeterminate in 20-50% of patients with NAFLD. We aimed to develop machine learning models to improve upon FIB4 and NFS, especially in the indeterminate-risk range.</p>

ESTABLISHING A PHARMACIST-LED HEPATITIS C TREATMENT CLINIC WITHIN A LARGE HEALTHCARE SYSTEM

<div><p><strong><b>Background:</strong> </b><span class="NormalTextRun SCXW107492957 BCX8">Hepatitis C Virus (HCV) is a blood-borne viral pathogen resulting in hepatic inflammation that – if left untreated – may lead to advanced liver disease, hepatocellular carcinoma, and death. With the advent of improved treatment modalities, several national, state, and local governing bodies have called for HCV eradication.

Subscribe to